Mutations conferring resistance to first-line anti-tuberculosis drugs in peru: A systematic review of the literature

0Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Objective. To systematize available information regarding mutations that confer resistance to first-line anti-tuberculosis drugs. Materials and Methods. A systematic review of the scientific literature was conducted to identify articles that reported mutations conferring resistance to first-line anti-tuberculosis drugs. This search emphasized resistance to isoniazid and rifampicin drugs in M. tuberculosis strains of Peruvian patients. The search was performed on PubMed and LILACS (Latin American and Caribbean Health Sciences Literature). Results. Fourteen (14) articles were included, of which three reported mutations associated with resistance to isoniazid, six to rifampicin, eight to pyrazinamide and one to ethambutol. All mutations to isoniazid or rifampicin were identified directly or indirectly by the molecular diagnostic test GenoType MTBDRplus® v2.0. The greatest variability of mutations was determined in resistance to pyrazinamide. Conclusions. There is a great variability of mutations associated with resistance to anti-tuberculosis drugs that have been reported in Peru, and they are systematized in this report. These mutations must be taken into account for the development of diagnostic devices or selection of diagnostic tests to be applied in our country.

Cite

CITATION STYLE

APA

Vigo, A., Solari, L., Santos, D., & Puyén, Z. M. (2019). Mutations conferring resistance to first-line anti-tuberculosis drugs in peru: A systematic review of the literature. Revista Peruana de Medicina Experimental y Salud Publica, 36(4), 636–645. https://doi.org/10.17843/rpmesp.2019.364.4722

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free